<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590820</url>
  </required_header>
  <id_info>
    <org_study_id>EPZ-6438-007-2019</org_study_id>
    <nct_id>NCT04590820</nct_id>
  </id_info>
  <brief_title>Oral Tazemetostat in Combination With Rituximab in R/R FL</brief_title>
  <official_title>A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to examine the feasibility and efficacy of adding the EZH2&#xD;
      inhibitor, Tazemetostat to rituixmab, standard second line or beyond therapy as a means to&#xD;
      improve disease response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1. Rituximab will be&#xD;
      administered by either subcutaneous injection or IV infusion according to the regional&#xD;
      product prescribing information and labeling. Rituximab will be administered at a dose of 375&#xD;
      mg/m2 on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting&#xD;
      for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was transferred to Epizyme under NCT04762160 and new study number EZH-1401&#xD;
  </why_stopped>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Actual">January 29, 2021</completion_date>
  <primary_completion_date type="Actual">January 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, non randomized, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate Objective response rate</measure>
    <time_frame>4 years</time_frame>
    <description>To determine the objective response rate (ORR; complete response + partial response [CR + PR]) of Tazemetostat in combination with Rituximab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Adverse events will be collected beginning at screening and then at all subsequent time points up to 4 years</time_frame>
    <description>This will be measured in accordance to National Cancer (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To estimate progression-free survival (PFS) rate of tazemetostat in combination with rituximab at 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tazemetostat + Rituxan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1.&#xD;
Rituximab will be administered by either Subcutaneous injection or IV infusion on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>tazemetostat is an oral, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2.</description>
    <arm_group_label>Tazemetostat + Rituxan</arm_group_label>
    <other_name>EPZ-6438</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab is a chimeric monoclonal antibody against the protein CD20. Given either Intravenous or subcutaneous.</description>
    <arm_group_label>Tazemetostat + Rituxan</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women of 18 years of age and older&#xD;
&#xD;
          2. Voluntary agreement to provide written informed consent and the willingness and&#xD;
             ability to comply with all aspects of the protocol.&#xD;
&#xD;
          3. Have histologically confirmed FL, grades 1 to 3a. Subjects may have&#xD;
             relapsed/refractory disease following at least 2 standard prior systemic treatment&#xD;
             regimen where at least 1 anti-CD20-based regimen was used.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) score of 0 &lt;/= 2&#xD;
&#xD;
          5. Treatment recommended in accordance with the GELF criteria due to the presence of at&#xD;
             least one of the following:&#xD;
&#xD;
               -  Any nodal or extranodal tumor mass &gt;7 cm diameter&#xD;
&#xD;
               -  Involvement of at least 3 nodal sites, each with diameter &gt;3 cm&#xD;
&#xD;
               -  Presence of any systemic or B symptoms&#xD;
&#xD;
               -  Splenic enlargement with inferior margin below the umbilical line&#xD;
&#xD;
          6. Compression syndrome (ureteral, orbital, gastrointestinal)&#xD;
&#xD;
          7. Pleural or peritoneal serous effusion (irrespective of cell content)&#xD;
&#xD;
          8. Leukemic phase (&gt;5.0 x 109/L circulating malignant cells)&#xD;
&#xD;
          9. Cytopenias (granulocyte count &lt;1.0 x 109/L and/or platelets &lt;100 x 109/L)&#xD;
&#xD;
         10. Meet the following laboratory parameters:&#xD;
&#xD;
               -  ANC ≥ 750 cells/μL (0.75 x 109/L), or ≥ 500 cells/μL (0.50 x 109/L) in subjects&#xD;
                  with documented bone marrow involvement&#xD;
&#xD;
               -  Platelet count ≥ 50,000 cells/μL (50 x 109/L), or ≥ 30,000 cells/μL (30 x 109/L)&#xD;
                  in subjects with documented bone marrow involvement, and without transfusion&#xD;
                  dependence.&#xD;
&#xD;
               -  Serum AST and ALT/SGPT ≤ 3.0 x ULN, unless related to disease involvement&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN, unless due to disease involvement, Gilbert's, or&#xD;
                  hemolytic anemia).&#xD;
&#xD;
               -  Estimated creatinine clearance (ie, eGFR using Cockcroft-Gault) ≥ 40 mL/min.&#xD;
&#xD;
         11. No prior therapy with EZH2 inhibitors&#xD;
&#xD;
         12. At least one bi-dimensionally measurable nodal lesion &gt; 1.5 cm in its longest diameter&#xD;
             by CT scan or MRI excluding lesions that meet the following criteria&#xD;
&#xD;
               -  Previously irradiated lesions should not be counted as target lesions&#xD;
&#xD;
               -  Lesions that are intended to be used to collect tissue samples for biopsy should&#xD;
                  not be counted as target lesions&#xD;
&#xD;
               -  Bone lesions should not be counted as target lesions&#xD;
&#xD;
         13. All clinically significant treatment-related toxicity from prior therapy, except for&#xD;
             alopecia, resolved to ≤ Grade 1 or to a new stable baseline&#xD;
&#xD;
         14. Female subjects of reproductive potential must have a negative urine/serum\ pregnancy&#xD;
             test upon study entry. Female subjects who are of non-reproductive potential (ie,&#xD;
             post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR&#xD;
             history of bilateral tubal ligation; OR history of bilateral oophorectomy) are exempt&#xD;
             from pregnancy testing.&#xD;
&#xD;
         15. Male and female subjects of reproductive potential who agree to use both a highly&#xD;
             effective method of birth control (eg, implants, injectables, combined oral&#xD;
             contraceptives, some intrauterine devices [IUDs], complete abstinence1, or sterilized&#xD;
             partner) and a barrier method (eg, condoms, cervical ring, sponge, etc) during the&#xD;
             period of therapy and for 12 months after the last dose of rituximab.&#xD;
&#xD;
         16. Men and women must agree to refrain from sperm or oocyte donation during the study and&#xD;
             for 12 months after the last dose of rituximab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia&#xD;
&#xD;
          2. Transformed Follicular lymphoma&#xD;
&#xD;
          3. Any uncontrolled illness including, but not limited to, significant active infections,&#xD;
             hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction&#xD;
&#xD;
          4. Subjects who have tested positive for hepatitis B surface antigen and/or hepatitis B&#xD;
             core antibody plus have a hepatitis B polymerase chain reaction (PCR) assay (subjects&#xD;
             with a negative PCR assay are permitted with appropriate anti-viral prophylaxis)&#xD;
&#xD;
          5. Positive for hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV)&#xD;
             antibody; subjects with positive hepatitis C antibody are eligible if they are&#xD;
             negative for hepatitis C virus by PCR&#xD;
&#xD;
          6. Other diagnosis of cancer that is likely to require treatment in the next 2 years,&#xD;
             with the exception of the following:&#xD;
&#xD;
               -  Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Curatively treated carcinoma in situ of the cervix&#xD;
&#xD;
               -  Hormonal therapy for prostate cancer&#xD;
&#xD;
          7. History of clinically significant cardiovascular abnormalities such as congestive&#xD;
             heart failure (New York Heart Association classification ≥ 2), myocardial infarction&#xD;
             within 6 months of study entry&#xD;
&#xD;
          8. History of clinically significant gastrointestinal (GI) conditions, particularly:&#xD;
&#xD;
               -  Known GI condition that would interfere with swallowing or the oral absorption or&#xD;
                  tolerance of study drug&#xD;
&#xD;
               -  Pre-existing malabsorption syndrome or other clinical situation that would affect&#xD;
                  oral absorption&#xD;
&#xD;
          9. Females who are currently breastfeeding&#xD;
&#xD;
         10. Received a live virus vaccination within 28 days of first dose of Rituxan&#xD;
&#xD;
         11. Participation in a separate investigational therapeutic study&#xD;
&#xD;
         12. Psychiatric illness/social situations that would interfere with study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krish Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swedish Cancer Institute Edmonds Campus</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute Issaquah Campus</name>
      <address>
        <city>Issaquah</city>
        <state>Washington</state>
        <zip>98029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Cancer Institute - First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

